Effects of local delivery of d-amino acids from biofilm-dispersive scaffolds on infection in contaminated rat segmental defects

Biomaterials

Volumn 34, Issue 30, 2013, Pages 7533-7543

  Sanchez, Carlos J ^a   Prieto, Edna M ^b,c   Krueger, Chad A ^a   Zienkiewicz, Katarzyna J ^c   Romano, Desiree R ^a   Ward, Catherine L ^a   Akers, Kevin S ^a   Guelcher, Scott A ^b,c   Wenke, Joseph C ^a  

^a US ARMY INSTITUTE OF SURGICAL RESEARCH   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biofilm; Dispersal agent; Open fracture; Osteomyelitis; Scaffold; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC THERAPY; BACTERIAL CONTAMINATION; CHRONIC INFECTION; EQUIMOLAR MIXTURES; OSTEOMYELITIS; POLYURETHANE SCAFFOLDS; STAPHYLOCOCCUS AUREUS; THERAPEUTIC STRATEGY;

AMINO ACIDS; BACTERIA; CONTAMINATION; FRACTURE; MIXTURES; RATS; SCAFFOLDS; SURFACE DEFECTS;

BIOFILMS;

DEXTRO AMINO ACID; DISPERSANT; MOLECULAR SCAFFOLD; POLYURETHAN;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ADHERENCE; BACTERIUM CONTAMINATION; BIOFILM; CELL VIABILITY; CYTOTOXICITY; FIBROBLAST; FRACTURE HEALING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFECTIOUS COMPLICATION; NONHUMAN; OPEN FRACTURE; PATHOGEN LOAD; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS AUREUS; SYNTHESIS;

BIOFILM; DISPERSAL AGENT; OPEN FRACTURE; OSTEOMYELITIS; SCAFFOLD; STAPHYLOCOCCUS AUREUS;

AMINO ACIDS; ANIMALS; BIOFILMS; CELL DEATH; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMUR; HUMANS; POLYURETHANES; RATS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TISSUE SCAFFOLDS;

BACTERIA (MICROORGANISMS); RATTUS; STAPHYLOCOCCUS AUREUS;

EID: 84880513196     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.06.026     Document Type: Article

References (71)

1. Lew D.P., Waldvogel F.A. Osteomyelitis. Lancet 2004, 364:369-379.
2. Conterno L.O., da Silva Filho C.R. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev 2009, CD004439.
3. Huh J., Stinner D.J., Burns T.C., Hsu J.R. Infectious complications and soft tissue injury contribute to late amputation after severe lower extremity trauma. JTrauma 2011, 71:S47-S51.
4. Costerton J.W. Biofilm theory can guide the treatment of device-related orthopaedic infections. Clin Orthop Relat Res 2005, 7-11.
5. Costerton J.W., Stewart P.S., Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science 1999, 284:1318-1322.
6. Brady R.A., Leid J.G., Calhoun J.H., Costerton J.W., Shirtliff M.E. Osteomyelitis and the role of biofilms in chronic infection. FEMS Immunol Med Microbiol 2008, 52:13-22.
7. Marrie T.J., Costerton J.W. Mode of growth of bacterial pathogens in chronic polymicrobial human osteomyelitis. JClin Microbiol 1985, 22:924-933.
8. Gristina A.G., Oga M., Webb L.X., Hobgood C.D. Adherent bacterial colonization in the pathogenesis of osteomyelitis. Science 1985, 228:990-993.
9. Costerton J.W. Introduction to biofilm. Int J Antimicrob Agents 1999, 11:217-221. discussion 37-9.
10. del Pozo J.L., Patel R. The challenge of treating biofilm-associated bacterial infections. Clin Pharmacol Ther 2007, 82:204-209.
11. Hall-Stoodley L., Costerton J.W., Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004, 2:95-108.
12. Esteban J., Molina-Manso D., Spiliopoulou I., Cordero-Ampuero J., Fernandez-Roblas R., Foka A., et al. Biofilm development by clinical isolates of Staphylococcus spp. from retrieved orthopedic prostheses. Acta Orthop 2010, 81:674-679.
13. O'Neill E., Pozzi C., Houston P., Smyth D., Humphreys H., Robinson D.A., et al. Association between methicillin susceptibility and biofilm regulation in Staphylococcus aureus isolates from device-related infections. JClin Microbiol 2007, 45:1379-1388.
14. Sanchez C.J., Mende K., Beckius M.L., Akers K.S., Romano D.R., Wenke J.C., et al. Biofilm formation by clinical isolates and the implications in chronic infections. BMC Infect Dis 2013, 13:47.
15. Palmer M., Costerton W., Sewecke J., Altman D. Molecular techniques to detect biofilm bacteria in long bone nonunion: a case report. Clin Orthop Relat Res 2011, 469:3037-3042.
16. McDougald D., Rice S.A., Barraud N., Steinberg P.D., Kjelleberg S. Should we stay or should we go: mechanisms and ecological consequences for biofilm dispersal. Nat Rev Microbiol 2012, 10:39-50.
17. Hall-Stoodley L., Stoodley P. Biofilm formation and dispersal and the transmission of human pathogens. Trends Microbiol 2005, 13:7-10.
18. Kaplan J.B. Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses. JDent Res 2010, 89:205-218.
19. Lynch A.S., Abbanat D. New antibiotic agents and approaches to treat biofilm-associated infections. Expert Opin Ther Patents 2010, 20:1373-1387.
20. Folsom J.P., Baker B., Stewart P.S. Invitro efficacy of bismuth thiols against biofilms formed by bacteria isolated from human chronic wounds. JAppl Microbiol 2011, 111:989-996.
21. Kaplan J.B., LoVetri K., Cardona S.T., Madhyastha S., Sadovskaya I., Jabbouri S., et al. Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci. JAntibiot 2012, 65:73-77.
22. Dow J.M., Crossman L., Findlay K., He Y.Q., Feng J.X., Tang J.L. Biofilm dispersal in Xanthomonas campestris is controlled by cell-cell signaling and is required for full virulence to plants. Proc Natl Acad Sci U S A 2003, 100:10995-11000.
23. Jennings J.A., Courtney H.S., Haggard W.O. Cis-2-decenoic acid inhibits S.aureus growth and biofilm invitro: a pilot study. Clin Orthop Relat Res 2012, 470:2663-2670.
24. Simonetti O., Cirioni O., Ghiselli R., Goteri G., Scalise A., Orlando F., et al. RNAIII-inhibiting peptide enhances healing of wounds infected with methicillin-resistant Staphylococcus aureus. Antimicrobial Agents Chemother 2008, 52:2205-2211.
25. Brackman G., Cos P., Maes L., Nelis H.J., Coenye T. Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics invitro and invivo. Antimicrobial Agents Chemother 2011, 55:2655-2661.
26. Kolodkin-Gal I., Romero D., Cao S., Clardy J., Kolter R., Losick R. D-amino acids trigger biofilm disassembly. Science 2010, 328:627-629.
27. Hochbaum A.I., Kolodkin-Gal I., Foulston L., Kolter R., Aizenberg J., Losick R. Inhibitory effects of D-amino acids on Staphylococcus aureus biofilm development. JBacteriol 2011, 193:5616-5622.
28. Ercal N., Luo X., Matthews R.H., Armstrong D.W. Invitro study of the metabolic effects of D-amino acids. Chirality 1996, 8:24-29.
29. Smeltzer M.S., Thomas J.R., Hickmon S.G., Skinner R.A., Nelson C.L., Griffith D., et al. Characterization of a rabbit model of staphylococcal osteomyelitis. JOrthop Res 1997, 15:414-421.
30. Weiss E.C., Zielinska A., Beenken K.E., Spencer H.J., Daily S.J., Smeltzer M.S. Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms invivo. Antimicrobial Agents Chemother 2009, 53:4096-4102.
31. Cassat J.E., Lee C.Y., Smeltzer M.S. Investigation of biofilm formation in clinical isolates of Staphylococcus aureus. Methods Mol Biol 2007, 391:127-144.
32. Christensen G.D., Simpson W.A., Younger J.J., Baddour L.M., Barrett F.F., Melton D.M., et al. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. JClin Microbiol 1985, 22:996-1006.
33. Guelcher S.A., Patel V., Gallagher K.M., Connolly S., Didier J.E., Doctor J.S., et al. Synthesis and invitro biocompatibility of injectable polyurethane foam scaffolds. Tissue Eng 2006, 12:1247-1259.
34. Sawhney A.S., Hubbell J.A. Rapidly degraded terpolymers of dl-lactide, glycolide, and epsilon-caprolactone with increased hydrophilicity by copolymerization with polyethers. JBiomed Mater Res 1990, 24:1397-1411.
35. Guelcher S., Srinivasan A., Hafeman A., Gallagher K., Doctor J., Khetan S., et al. Synthesis, invitro degradation, and mechanical properties of two-component poly(ester urethane)urea scaffolds: effects of water and polyol composition. Tissue Eng 2007, 13:2321-2333.
36. Hafeman A., Li B., Yoshii T., Zienkiewicz K., Davidson J., Guelcher S. Injectable biodegradable polyurethane scaffolds with release of platelet-derived growth factor for tissue repair and regeneration. Pharm Res 2008, 25(10):2387-2399.
37. Bhandare P., Madhavan P., Rao B.M., Someswar Rao N. Determination of amino acid without derivatization by using HPLC-HILIC column. JChem Pharm Res 2010, 2:372-380.
38. Kinnari T.J., Esteban J., Martin-de-Hijas N.Z., Sanchez-Munoz O., Sanchez-Salcedo S., Colilla M., et al. Influence of surface porosity and pH on bacterial adherence to hydroxyapatite and biphasic calcium phosphate bioceramics. JMed Microbiol 2009, 58:132-137.
39. Li B., Brown K.V., Wenke J.C., Guelcher S.A. Sustained release of vancomycin from polyurethane scaffolds inhibits infection of bone wounds in a rat femoral segmental defect model. JControl Release 2010, 145:221-230.
40. Guelcher S.A., Brown K.V., Li B., Guda T., Lee B.H., Wenke J.C. Dual-purpose bone grafts improve healing and reduce infection. JOrthop Trauma 2011, 25:477-482.
41. Penn-Barwell J.G., Murray C.K., Wenke J.C. Early antibiotics and debridement independently reduce infection in an open fracture model. JBone Jt Sur Br 2012, 94-B:1-6.
42. Hospenthal D.R., Murray C.K., Andersen R.C., Bell R.B., Calhoun J.H., Cancio L.C., et al. Guidelines for the prevention of infections associated with combat-related injuries: 2011 update: endorsed by the Infectious Diseases Society of America and the Surgical Infection Society. JTrauma 2011, 71:S210-S234.
43. Papadopoulou V., Kosmidis K., Vlachou M., Macheras P. On the use of the Weibull function for the discernment of drug release mechanisms. Int J Pharm 2006, 309:44-50.
44. Li B., Yoshii T., Hafeman A.E., Nyman J.S., Wenke J.C., Guelcher S.A. The effects of rhBMP-2 released from biodegradable polyurethane/microsphere composite scaffolds on new bone formation in rat femora. Biomaterials 2009, 30:6768-6779.
45. Beardmore A.A., Brookds D.E., Wenke J.C., Thomas D.B. Effectiveness of local antibiotic delivery with an osteoinductive and osteoconductive bone-graft substitute. JBone Jt Sur 2005, 87A:107-112.
46. McKee M., Wild L., Schemitsch E., Waddell J. The use of an antibioticimpregnated, osteoconductive, bioabsorbable bone substitute in the treatment of infected long bone defects: early results of a prospective trial. JOrthop Trauma 2002, 16:622-627.
47. Radin S., Ducheyne P., Kamplain T., Tan B.H. Silica sol-gel for the controlled release of antibiotics. I. Synthesis, characterization, and invitro release. JBiomed Mater Res 2001, 57:313-320.
48. Noel S.P., Courtney H.S., Bumgardner J.D., Haggard W.O. Chitosan sponges to locally deliver amikacin and vancomycin: a pilot invitro evaluation. Clin Orthop Relat Res 2010, 468:2074-2080.
49. Feng K., Sun H., Bradley M.A., Dupler E.J., Giannobile W.V., Ma P.X. Novel antibacterial nanofibrous PLLA scaffolds. JControl Release 2010, 146:363-369.
50. Virto M.R., Elorza B., Torrado S., Elorza Mde L., Frutos G. Improvement of gentamicin poly(D, L-lactic-co-glycolic acid) microspheres for treatment of osteomyelitis induced by orthopedic procedures. Biomaterials 2007, 28:877-885.
51. Radin S., Chen T., Ducheyne P. The controlled release of drugs from emulsified, sol gel processed silica microspheres. Biomaterials 2009, 30:850-858.
52. Shi X., Wang Y., Ren L., Zhao N., Gong Y., Wang D.A. Novel mesoporous silica-based antibiotic releasing scaffold for bone repair. Acta Biomater 2009, 5:1697-1707.
53. Tuomanen E., Cozens R., Tosch W., Zak O., Tomasz A. The rate of killing of Escherichia coli by beta-lactam antibiotics is strictly proportional to the rate of bacterial growth. JGen Microbiol 1986, 132:1297-1304.
54. Gristina A.G., Naylor P., Myrvik Q. Infections from biomaterials and implants: a race for the surface. Med Prog Technol 1988, 14:205-224.
55. Percival S.L., Hill K.E., Malic S., Thomas D.W., Williams D.W. Antimicrobial tolerance and the significance of persister cells in recalcitrant chronic wound biofilms. Wound Repair Regen 2011, 19:1-9.
56. Alipour M., Suntres Z.E., Lafrenie R.M., Omri A. Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes. JAntimicrob Chemother 2010, 65:684-693.
57. Hentzer M., Givskov M. Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections. JClin Invest 2003, 112:1300-1307.
58. Irukayama-Tomobe Y., Tanaka H., Yokomizo T., Hashidate-Yoshida T., Yanagisawa M., Sakurai T. Aromatic D-amino acids act as chemoattractant factors for human leukocytes through a G protein-coupled receptor, GPR109B. Proc Natl Acad Sci U S A 2009, 106:3930-3934.
59. Hafeman A.E., Zienkiewicz K.J., Zachman A.L., Sung H.J., Nanney L.B., Davidson J.M., et al. Characterization of the degradation mechanisms of lysine-derived aliphatic poly(ester urethane) scaffolds. Biomaterials 2011, 32(2):419-429.
60. Hafeman A.E., Zienkiewicz K.J., Carney E., Litzner B., Stratton C., Wenke J.C., et al. Local delivery of tobramycin from injectable biodegradable polyurethane scaffolds. JBiomater Sci Polym Ed 2010, 21:95-112.
61. Brown K.V., Li B., Guda T., Perrien D.S., Guelcher S.A., Wenke J.C. Improving bone formation in a rat femur segmental defect by controlling bone morphogenetic protein-2 release. Tiss Eng Part A 2011, 17:1735-1746.
62. Dumas J.E., Zienkiewicz K., Tanner S.A., Prieto E.M., Bhattacharyya S., Guelcher S. Synthesis and characterization of an injectable allograft bone/polymer composite bone void filler with tunable mechanical properties. Tis Eng Part A 2010, 16:2505-2518.
63. Dumas J.E., Brownbaer P.B., Prieto E.M., Guda T., Hale R.G., Wenke J.C., et al. Injectable reactive biocomposites for bone healing in critical-size rabbit calvarial defects. Biomed Mater 2012, 7:024112.
64. Li B., Davidson J.M., Guelcher S.A. The effect of the local delivery of platelet-derived growth factor from reactive two-component polyurethane scaffolds on the healing in rat skin excisional wounds. Biomaterials 2009, 30:3486-3494.
65. Nelson C.E., Gupta M.K., Adolph E.J., Shannon J.M., Guelcher S.A., Duvall C.L. Sustained local delivery of siRNA from an injectable scaffold. Biomaterials 2012, 33:1154-1161.
66. Nozaki Y., Tanford C. The solubility of amino acids and two glycine peptides in aqueous ethanol and dioxane solutions. Establishment of a hydrophobicity scale. JBiol Chem 1971, 246:2211-2217.
67. Liu C., Bayer A., Cosgrove S.E., Daum R.S., Fridkin S.K., Gorwitz R.J., et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011, 52:285-292.
68. Stewart R.L., Cox J.T., Volgas D., Stannard J., Duffy L., Waites K.B., et al. The use of a biodegradable, load-bearing scaffold as a carrier for antibiotics in an infected open fracture model. JOrthop Trauma 2010, 24:587-591.
69. Zheng Z., Yin W., Zara J.N., Li W., Kwak J., Mamidi R., et al. The use of BMP-2 coupled - Nanosilver-PLGA composite grafts to induce bone repair in grossly infected segmental defects. Biomaterials 2010, 31:9293-9300.
70. Wenke J.C., Guelcher S.A. Dual delivery of an antibiotic and a growth factor addresses both the microbiological and biological challenges of contaminated bone fractures. Exp Opin Drug Deliv 2011, 8:1555-1569.
71. Brown K.V., Walker J.A., Cortez D.S., Murray C.K., Wenke J.C. Earlier debridement and antibiotic administration decrease infection. JSurg Ortho Adv 2010, 19:18-22.